Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/26/2008

ner Professor of Psychiatry and Neuroscience at Baylor College of Medicine, and Dr. Richard Rawson of the University of California, Los Angeles' Department of Psychiatry. Drs. Kosten and Rawson are both key opinion leaders in the field of substance abuse and are contributing greatly to the achievement of Catalyst's goals."

"We are especially pleased that the positive results from our Mexico trial were discussed in Newsweek magazine's cover article on addiction in the March 3, 2008 issue. In the article, one of the foremost experts in the field of addiction noted that the results of this trial provide the best efficacy signal of any trial conducted so far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that are hardest to treat -- long-term cocaine addicts. We believe strongly in the viability of our technology and the promise that treatment with CPP-109 may bring to patients, the healthcare system and society at large."

Financial Results

For the year ended December 31, 2007, the Company's net loss was $4,139,493, or $0.33 per basic and diluted share, compared to a net loss of $2,729,454, or $0.36 per basic and diluted share, in the prior year. Results for 2007 and 2006 include non-cash charges relating to stock-based compensation of $556,343 and $1,220,739, respectively.

Research and development expenses for 2007 were $2,990,659, compared to $1,087,144 in 2006. This includes non-cash stock-based compensation for 2007 and 2006 of $365,107 and $344,649, respectively.

General and administrative expenses for 2007 were $2,036,470, compared to $1,815,183 in 2006. This includes non-cash stock-based compensation for 2007 and 2006 of $191,236 and $876,090, respectively.

For the fourth quarter of 2007, the Company's net loss was $944,938, or $0.08 per basic and diluted share, compared to a net loss of $741,241, or $0.07 per basic and diluted share, for the same period in 2006. Res
'/>"/>

SOURCE Catalyst Pharmaceutical Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , August 28, 2015 The ... in collaboration with one of the leading academics in the ... (current world record holder in life extension for model animals ... into biology of aging and age-related diseases, primarily, around the ... work has just been published as "Stability analysis of a ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el  Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Oct. 5 Osseon Therapeutics, Inc. announced its ... North American Spine Society,s (NASS) annual meeting in ... facilitate treatment of vertebral compression fractures (VCFs) that ... fibrotic metastases.  The Osseoflex DR Steerable Bone Drill ...
... SUNNYVALE, Calif., Oct. 5 Accuray Incorporated (Nasdaq: ... of radiosurgery, announced today that the company was awarded a ... U.S. Government to be used toward further development of a ... grant will fund the development of a next generation, compact ...
Cached Medicine Technology:Osseon® Therapeutics Introduces New Osseoflex® DR Steerable Bone Drill 2Accuray Awarded $1 Million Grant by U.S. Government 2Accuray Awarded $1 Million Grant by U.S. Government 3
(Date:8/30/2015)... ... 2015 , ... Scientists in France say asbestos exposure may put workers at ... Mesothelioma has just posted an article on the new research. Click here to ... incidence among 2,024 French asbestos plant workers from 1978 to 2009. In addition to ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale Avene ... , “Before, a threshold of $49.00 was required to qualify for free standard shipping,” ... free standard shipping for customers regardless of the item’s selling price.” , With competitive ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... a small molecule that can turn the survival signal for ... molecule mimics the activity of Smac, a protein that triggers ... researchers say their findings suggest that Smac-mimetic compounds could be ... Such therapy may be less toxic to healthy cells than ...
... Zero In on Rac1, Rac2 Genes as ... Molecular Targets, ... of Cancer Cell, researchers at Cincinnati Children,s Hospital Medical,Center reported that they ... spread of chronic myelogenous leukemia,(CML) in mice. When these genes, Rac1 ...
... 12 The American Cancer Society,is looking for individuals ... personal interest in the battle against cancer to serve ... be funded by the,organization,s research and training grants. These ... such as having had a,family member with cancer, having ...
... Stock Exchange Symbol: AKL, MONTREAL, Nov. 12 ... development company focused on developing therapies for the,inhalation ... from,its pilot GHRH Phase II study. Within only ... significant stimulation of endogenous growth hormone (GH),secretion and ...
... International,Isotopes Inc. (OTC Bulletin Board: INIS) announces ... ending September 30, 2007. REVENUE: Revenue for ... was $1,486,112 and $3,592,049 respectively, as compared to,$1,458,260 ... These numbers,represent an increase of 2% for the ...
... Nov. 12 HLM Venture Partners announced today,that it ... financing of,CaseNET, Inc. CaseNET, based in Waltham, MA, is ... enterprises and government,agencies a software solution for medical and ... $4 million to the round and was joined,by existing ...
Cached Medicine News:Health News:Smac-ing lung cancer to death 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 2Health News:Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia 3Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 3Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 4Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 5Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 4Health News:HLM Venture Partners Leads Series B Financing of CaseNET, Inc. 2
... anyone using the Farnsworth D15, L'Anthony desaturated test ... patients cannot avoid touching the color disks with ... Further, the disks are very easy to loose.,We ... in order to solve these problems. We have ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: